Fig. 5

Circulating circMET in cancer patients correlates with the MET status of the corresponding tissue biopsies. a, b Immunohistochemical analysis of low- (a) and high- (b) MET-expressing human lung adenocarcinomas and mouse rhabdomyosarcoma (Mouse) specimens with the indicated antibodies (scale bar = 100 μm). c Dot plot of circMET levels measured by real-time PCR in FFPE tumor samples (n = 12). Samples included in the analysis are listed in Table S2. **P < 0.01, Student’s t test. Data are expressed as mean ± SEM. d In situ detection of circMET in a MET-amplified FFPE tumor sample (case #4) using padlock probes and rolling circle amplification (scale bar = 25 μm). e Absolute quantification of circMET levels measured by digital PCR in the indicated liquid biopsies of cancer patients (n = 16) and healthy donors (HD) (n = 2). Each sample was analyzed in duplicate: both circMET values are shown for each patient (colored dots), along with their average value (black lines) and SEM. Low and high circMET expressors are indicated in violet/green and red, respectively. Clinical information of the primary human samples analyzed is provided in Table S2